Significant, rapid, and durable improvements in QoL1
Patients treated with JAKAVI experienced durable improvement in QoL at 3-year follow-up1
Adapted from: Verstovsek S et al. Abstract handout presented at: American Society of Hematology Annual Meeting, 2013.1
Based on a prespecified exploratory endpoint.
- At 3-year follow-up, patients treated with JAKAVI experienced durable improvements in the Global Health Status/QoL and functional domains of the EORTC QLQ-C301
JAKAVI Treatment in Clinical Practice: Managing severe MF-related fatigue
Fatigue is a debilitating symptom, present in a large majority of patients with MF, and can severely impact patient quality of life. Watch the video below to learn more from Dr Ruben Mesa about managing MF-related fatigue with JAKAVI.